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Aims A hallmark of Fabry disease is the concomitant development of left-ventricular hypertrophy and arterial intima–
media thickening, the pathogenesis of which is thought to be related to the presence of a plasmatic circulating
growth-promoting factor. We therefore characterized the plasma of patients with Fabry disease in order to identify
this factor.
Methods
and results
Using a classical biochemical strategy, we isolated and identified sphingosine-1 phosphate (S1P) as a proliferative
factor present in the plasma of patients with Fabry disease. Plasma S1P levels were significantly higher in 17 patients
with Fabry disease compared with 17 healthy controls (225+ 40 vs. 164+ 17 ng/mL; P ¼ 0.005). There was a
positive correlation between plasma S1P levels and both common carotid artery intima–media thickness and left-
ventricular mass index (r2 ¼ 0.47; P ¼ 0.006 and r2 ¼ 0.53; P ¼ 0.0007, respectively). In an experimental model,
mice treated with S1P developed cardiovascular remodelling similar to that observed in patients with Fabry disease.
Conclusion Sphingosine-1 phosphate participates in cardiovascular remodelling in Fabry disease. Our findings have implications
for the treatment of cardiovascular involvement in Fabry disease.
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Introduction
Fabry disease is an X-linked lysosomal storage disorder caused by
deficiency of the hydroxylase a-galactosidase A. The disease is
characterized by progressive accumulation of neutral glycosphingo-
lipids, mainly globotriaosylceramide (Gb3), in the plasma and
within many cell types, including endothelial cells, vascular
smooth muscle cells (VSMCs), and cardiomyocytes.1 During child-
hood, early signs and symptoms include neuropathic pain, angio-
keratomas, hypohidrosis, and gastrointestinal dysfunction. In
adulthood, involvement of the microvasculature of the kidney,
brain, and heart leads to renal failure, ischaemic stroke, and cardi-
ovascular dysfunction.2 Although the condition is X-linked, hetero-
zygous females are also affected, and may even exhibit the full
range of disease manifestations, but typically with a later onset
than in males.2,3
Cardiovascular remodelling, independent of changes in blood
pressure, is a hallmark of Fabry disease and occurs to a similar
degree in male and female patients.4 The main cardiac finding is
concentric left-ventricular hypertrophy (LVH), which usually devel-
ops during or after the third decade of life.5 Affected patients may
ultimately develop progressive heart failure, mostly due to diastolic
dysfunction.6 Patients may also present with a marked and
accelerated increase in intima–media thickness (IMT) of the
radial, brachial, and common carotid arteries (CCA), as well as
of the aorta.4,7,8
Left-ventricular hypertrophy and increased CCA IMT occur
concomitantly in patients with Fabry disease suggesting a
common pathogenesis.4 As the amount of Gb3 deposited rep-
resents only a fraction of the abnormal left ventricle and arterial
wall thickening (around 1–3%), a mechanism(s) other than lipid
deposition must be considered in the pathogenesis of the
* Corresponding author. Tel: þ41 21 314 07 73, Fax: þ41 21 314 07 61, Email: noureddine.brakch@chuv.ch (N.B.); Tel: þ41 21 314 76 06, Fax: þ41 21 314 11 75,
Email: frederic.barbey@chuv.ch (F.B.)
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.
European Heart Journal (2010) 31, 67–76
doi:10.1093/eurheartj/ehp387
cardiovascular remodelling associated with this condition.9,10
Consistent with this hypothesis, we found previously that plasma
from patients with Fabry disease contains a growth-promoting
factor that induces VSMC and cardiomyocyte proliferation in vitro.4
In this report, we have further characterized the plasma of male
and female patients with Fabry disease and identified sphingosine-1
phosphate (S1P) as a potent growth-promoting factor that partici-
pates in both the cardiac and arterial remodelling associated with
the disease.
Methods
This study was approved by the Institutional Review Board of the local
ethic committees and complies with the Declaration of Helsinki. All
human subjects provided written informed consent. All animal exper-
iments were performed in accordance with the Swiss federal animal
regulations and approved by the veterinary office of Vaud.
Study participants
Seventeen adults with Fabry disease (9 men: age range, 25–56 years; 8
women: age range, 24–61 years) from the cohort of patients followed
at the Centre Hospitalier Universitaire Vaudois in Lausanne were
enrolled in the study. No patient was receiving enzyme replacement
therapy (ERT) at baseline. Both groups are part of populations that
have been previously described.4 All hemizygous males had the
classic form of the disease, based on clinical manifestations and the
detection of a-galactosidase A levels ,1.5 nmol/h per mL plasma.
Diagnosis of heterozygous females was confirmed by mutation analysis.
To determine the normal plasma level of S1P, 17 healthy individuals,
matched for sex and age, were studied. Blood pressure, IMT measure-
ments, and laboratory studies were performed in all patients and
healthy controls, and echocardiography in all patients. Left-ventricular
mass (LVM) index was measured in the patients and compared with
normal reference values according to guidelines of the European
society of cardiology.11
Reagents
Sphingosine-1 phosphate was purchased from Avantis Polar Lipids,
anti-a-actinin antibody from Novocastra, and anti-atrial natriuretic
peptide (ANP) antibody from Biomol International.
Cell culture and measurement of vascular
smooth muscle cell proliferation
Vascular smooth muscle cells from Wistar rat aorta were isolated and
cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing
10% fetal bovine serum and antibiotics, as previously described.4 Vas-
cular smooth muscle cells were seeded on 96-well plates and incu-
bated for 12 h. Cells were subsequently washed and incubated with
various concentrations of S1P. Cell proliferation was quantified using
the cell titre 96 Aqueous non-radioactive cell proliferation assay
(promega) following the manufacturer’s instructions.
Plasma lipid fraction extraction and
fractionation
To identify the circulating growth-promoting factor(s), we isolated the
lipid fraction in pooled plasma samples from the 17 patients with Fabry
disease and 17 matched healthy individuals. Vascular smooth muscle
cells were exposed to extracted plasma and proliferation was
measured using the soluble tetrazolium salt (MTS) assay. Fresh hepar-
inized human blood was centrifuged at 3000g for 5 min at 48C. Cell-
free plasma was removed and centrifuged at 14 000g for 5 min at
48C. Each plasma sample was extracted by rocking with 20 volumes
of chloroform:methanol (2:1) for 15 min at 378C and then centrifuged
at 14 000g for 5 min at 48C. The supernatants were transferred to
fresh tubes, partitioned against one-fifth volume of distilled water at
48C, and stored overnight prior to two-phase separation. The upper
phase was removed following centrifugation and dried under nitrogen.
The dry residue was resuspended in 400 mL of serum-free medium and
100 mL applied to cultured VSMCs seeded on a 96-well plate. Cells
were cultured for 18 h and proliferation was quantified as described
above.
A sample of 5 mL heparinized plasma from five patients was distrib-
uted in 2 mL ependorf tubes in 50 mL aliquots then extracted as
described earlier. Each of 20 tubes (1 mL of plasma) of dried residues
were resuspended in 1 mL water trifluoroacetic acid 1‰ and applied
on C18 Sep-Pak cartridge, which was pre-equilibrated with water tri-
fluoroacetic acid 1‰. The bound material was eluted with different
concentrations of acetonitrile (0, 20, 40, 60, and 80%). An aliquot of
25 mL from each fraction was dried and resuspended in DMEM then
applied to VSMCs; this step was replicated three times.
The highly active fractions from extracted Fabry plasma between 0
and 20% were mixed, dried and resuspended in 40% acetonirile/60%
trifluoroacetic acid 1‰ in water. The obtained material was fractio-
nated by gel filtration HPLC using two columns (two protein-pak 60
in tandem, Macrosphere GPC 60 A 7u Alltech) at a flow rate of
0.5 mL/min. An aliquot of 25 mL from each fraction was dried and
resuspended in DMEM then applied to VSMC, this was carried out
in triplicate. The tandem column was calibrated with somatostatin-28
(3000 Da) and somatostatin-14 (1500 Da).
The highly active fractions of plasma from patients with Fabry
disease were mixed, dried, and resuspended in chloroform/methanol
(70/30%). The obtained material was fractionated by HPLC on a
Vydac C18 column. Elution was performed in isocratic chloroform/
methanol (70/30%) for 15 min followed with a linear gradient of
methanol at a flow rate of 1 mL/min from 30 to 60% in 5 min.
Mass spectrometry analysis
The lipid fraction of plasma from patients with Fabry disease were
mixed, dried, resuspended in acetonitrile/acetic acid and analysed by
electrospray ionization mass spectrometry (ESI-MS). Electrospray ion-
ization mass spectrometry analysis was performed with a linear ion
trap mass spectrometer (Thermo-Fisher), operating in positive ion
mode, with data collected from 50 to 1000 amu.
Circulating plasma sphingosine-1 phosphate
measurement
Sphingosine-1 phosphate was first measured using solid-phase extrac-
tion followed by derivatization with o-phthalaldehyde and fluorescence
detection, as described by Butter et al.12
Blood pressure measurements, tissue
analysis, and immunohistochemical staining
in a Fabry mouse model
One hundred and twenty-nine strain mice were obtained from the
Jackson Laboratory. Ten-week-old mice were injected intraperitonealy
with S1P 0.4 mg/kg/day (n ¼ 8) or with vehicle (phosphate buffered
saline; n ¼ 8) as a control for 4 weeks. Following 4 weeks of S1P treat-
ment, mean arterial blood pressure was measured in control and
S1P-treated mice, as described previously.13 Subsequently, mice were
killed by intravenous injection of pentobarbital 100 mg/kg. Hearts and
aorta were collected. Cardiac weight index was determined. Tissue
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samples were immersion-fixed in 4% paraformaldehyde, embedded in
paraffin, and serial sections were cut for haematoxylin–eosin, ANP,
and a-actin staining. Serial sections collected every 4 mm were analysed.
Aortic IMT was evaluated by computer-assisted morphometric analysis.
All measurements were performed in the same 16 mice.
Statistics
Results are reported as the mean+ SD unless otherwise indicated.
GraphPad Prism Software (San Diego, USA) was used for statistical
analysis. Groups were compared using the Kruskal–Wallis non-
parametric one-way analysis of variance and Mann–Whitney U tests.
Differences were considered significant where P-value was ,0.05.
Correlations between circulating levels of S1P and CCA IMT and
LVM index were assessed by regression analysis (Pearson product-
moment correlation coefficient).
Results
Study participants
The demographic and baseline clinical characteristics of the
patients and controls are shown in Table 1. The male Fabry
group differed significantly from the male control group in terms
of CCA IMT (725.8+117.0 vs. 594.0+62.0 mm; P ¼ 0.045).
There was no significant difference between the female Fabry
group and the female control group. An increase in LVM index
was observed in male and female patients with Fabry disease.
Plasma of patients with Fabry disease
induces vascular smooth muscle
cell proliferation
Extracted plasma from patients with Fabry disease significantly
increased VSMC proliferation compared with plasma from
healthy subjects (Figure 1A, n ¼ 17 P ¼ 0.0078). The most abun-
dant component present in the fractioned plasma of patients
with Fabry disease peaked at 380.6 Da, corresponding to the
mass of S1P (Figure 1B).
Plasma sphingosine-1 phosphate levels
are significantly increased in Fabry
patients compared with healthy subjects
Circulating S1P levels were significantly increased in patients with
Fabry disease compared with healthy controls (225+40 vs.
164+17 ng/mL; P ¼ 0.005) (Figure 2A). Males with Fabry disease
had significantly increased plasma S1P levels compared with
healthy males (213+ 31 vs. 161+19 ng/mL; P ¼ 0.008)
(Figure 2B). Sphingosine-1 phosphate concentrations were not sig-
nificantly different between heterozygous females and healthy
females (198.0+ 47.0 vs. 167.5+15.0 ng/mL, P ¼ 0.18);
however, some heterozygous females had S1P levels as high as
hemizygous males (Figure 2C).
Sphingosine-1 phosphate increases
vascular smooth muscle cell proliferation
in vitro in a dose-dependent manner
Sphingosine-1 phosphate significantly increased the proliferation of
VSMCs in a dose-dependent manner as evaluated with optic
density at 490 nm. Cell proliferation increased from 0.436+
0.0015 in the absence of S1P to 0.432+ 0.06 (P ¼ 0.7), 0.498+
0.035 (P ¼ 0.02), and 0.577+ 0.002 (P ¼ 0.007) with S1P concen-
trations of 100 nM, 1 mM, and 10 mM, respectively (Figure 3A). This
proliferative effect was present at S1P concentrations similar to
those measured in the plasma of the patients with Fabry disease.
At lower S1P concentrations (100 nM), the planar cell surface
area (PCSA) of VSMCs was increased (Figure 3B). This suggests a
hypertrophic mechanism at the origin of cardiac remodelling. In
contrast, at higher S1P concentrations, while VSMC PCSA was
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Table 1 Baseline clinical characteristics of the study populations
Parameters Males Females
Fabry (n 5 9) Controls
(n5 9)
P-value Fabry (n 5 8) Controls
(n 5 8)
P-value
Age (years) 42.8+8.8 50.0+7.0 NS 40.1+13.6 49.0+7.5 NS
Systolic blood pressure (mmHg) 126.1+12.3 118.0+6.7 NS 122.7+16.4 118.0+9.8 NS
Diastolic blood pressure (mmHg) 75.2+8.1 73.7+3.2 NS 74.5+5.9 69.4+4.9 NS
Serum total cholesterol (mmol/L) 5.20+0.99 4.81+0.72 NS 5.33+0.72 5.10+0.49 NS
Serum HDL-cholesterol (mmol/L) 1.48+0.29 1.50+0.44 NS 1.51+0.43 1.55+0.32 NS
Total/HDL-cholesterol ratio 3.59+0.25 2.90+0.65 NS 3.59+0.43 3.62+0.10 NS
Serum LDL-cholesterol (mmol/L) 3.13+0.95 3.0+0.54 NS 3.20+0.96 2.93+0.36 NS
Serum triglycerides (mmol/L) 1.27+0.56 1.10+0.43 NS 1.25+0.39 0.81+0.31 NS
Diabetes (n) 0 0 0 0
Smoking (%) 22.0 20.0 12.5 25.0
Left-ventricular mass index (g/m2) 149.6+64.3 (normal  115) – 104.9+39.3 (normal  96) –
Common carotid artery IMT
(mm)
725.8+117.3 594.6+62.4 0.045 709.4+193.7 586.7+81.4 NS
HDL, high-density lipoprotein; IMT, intima–media thickness; LDL, low-density lipoprotein.
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Figure 1 (A) Vascular smooth muscle cell proliferation is significantly increased in the presence of extracted lipid fraction from the plasma of
n ¼ 17 patients with Fabry disease compared with that from n ¼ 17 healthy subjects. Results are expressed in arbitrary units and represent the
mean of six experiments of absorbance at 490 nm, normalized with absorbance obtained from vascular smooth muscle cells incubated with
Dulbecco’s modified Eagle’s medium alone (P ¼ 0.0078). (B) Electrospray ionization mass spectrometry showed that the most abundant
plasma lipid compound peaked at 380.6 Da, corresponding to the mass of sphingosine-1 phosphate.
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Figure 2 (A) Plasma sphingosine-1 phosphate levels of n ¼ 17 healthy subjects vs. n ¼ 17 patients with Fabry disease (P ¼ 0.005). (B) Plasma
sphingosine-1 phosphate levels of n ¼ 9 healthy males vs. n ¼ 9 males with Fabry disease (P ¼ 0.008). (C) Plasma sphingosine-1 phosphate
levels of n ¼ 8 healthy females vs. n ¼ 8 females with Fabry disease.
Figure 3 (A) Proliferation of vascular smooth muscle cells exposed to different concentrations of sphingosine-1 phosphate. Results are expressed in
arbitrary units and represent the mean of six experiments of absorbance at 490 nm (P ¼ 0.02 and P ¼ 0.007 vs. untreated vascular smooth muscle
cells). (B) Progressive variation of planar cell surface area (PCSA) of vascular smooth muscle cells exposed to increasing concentrations of sphingosine-1
phosphate. PCSA was quantified by computer-assisted morphometry. Values are mean (+SD) PCSA of 150 cells. (C) Number of live vascular smooth
muscle cells exposed to increasing concentrations of sphingosine-1 phosphate as assessed by fluorescence-activated cell sorting (FACS).
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decreased, the number of cells increased as indicated by FACS
analysis (Figure 3C), suggesting hyperplasia.
Treatment of mice with sphingosine-1
phosphate increases aortic intima–media
thickness
Mean aortic IMT was significantly greater in S1P-treated mice than
controls (74.1+21.0 vs. 37.5+5.1 mm; P ¼ 0.0007) (Figure 4A).
Haematoxylin–eosin staining of the aortic wall revealed a normal
appearance and composition of the intima–media (Figure 4B).
The predominant cellular component of the intima–media was
VSMCs, as revealed by immunostaining for a-actin (Figure 4B).
Treatment of mice with sphingosine-1
phosphate induces cardiac hypertrophy
The cardiac weight index of S1P-treated mice was 27% greater
than that of control mice (P ¼ 0.03) (Figure 5A). The development
of cardiac hypertrophy was independent of blood pressure as
S1P-treated mice had a lower mean arterial blood pressure than
controls (Figure 5B). Furthermore, haematoxylin–eosin staining
showed a hypertrophic response of cardiomyocytes to S1P. This
was confirmed by the presence of diffuse ANP staining in
samples from S1P-treated mice compared with patchy staining in
control samples (Figure 5B).
Plasma sphingosine-1 phosphate levels
correlate with common carotid artery
intima–media thickness and
left-ventricular mass index
in Fabry patients
There was a positive correlation between circulating S1P levels and
CCA IMT in patients with Fabry disease (r2 ¼ 0.47; P ¼ 0.007,
Figure 6A). Plasma S1P levels also correlated positively with LVM
index in Fabry patients (r2 ¼ 0.53; P ¼ 0.0007, Figure 6B). Figure 6C
shows the correlation between S1P levels and CCA IMT (r2 ¼ 0.55;
P ¼ 0.0001) in males and females in the Fabry and control populations.
Figure 4 (A) Intima–media thickness (mm) in mice treated with vehicle (n ¼ 8 control) or sphingosine-1 phosphate (n ¼ 8 sphingosine-1
phosphate), 0.4 mg/kg/day intraperitoneally for 4 weeks (P ¼ 0.0007). (B) Haematoxylin–eosin and a-actin staining of aorta sections from
mice treated with vehicle or sphingosine-1 phosphate as under (A). Photomicrographs show representative sections of aorta. (Scale
bar ¼ 10 mM).
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Males with Fabry disease had a greater IMT and higher S1P-values
compared with male controls. The ranges of IMT and S1P-values
were greater in heterozygous females than in female controls.
Discussion
In the present study, we identified S1P as a biologically active
growth-promoting factor involved in cardiovascular remodelling
in both males and females with Fabry disease. Male patients had sig-
nificantly higher plasma S1P levels compared with healthy controls.
Moreover, there was a strong correlation between plasma S1P
levels and LVM index, and increased CCA IMT in patients with
Fabry disease. In addition, S1P-treated mice developed comparable
cardiovascular remodelling to that observed in patients with Fabry
disease.
We showed previously that vascular remodelling occurs to a
similar degree in male and female patients with Fabry disease.4
Patients with Fabry disease presented with a strong correlation
between LVM index and CCA IMT, in the absence of arterial
hypertension, suggesting a common pathogenesis to their develop-
ment. Using an in vitro assay, we demonstrated that plasma from
both males and females with Fabry disease induced proliferation
of rat VSMCs and neonatal mice cardiomyocytes.4 These results
suggested the existence of a circulating growth-promoting factor
in Fabry disease. In a recent paper, Aerts et al.14 reported that glo-
botriaosylsphingosine (lyso-Gb3) was markedly elevated in the
plasma of male Fabry patients but not in female patients. Interest-
ingly, exposure of VSMCs to lyso-Gb3 promoted cell proliferation.
However, the signalling pathway and cardiovascular expression of
lyso-Gb3 receptors remain elusive.
Figure 5 (A) Cardiac weight index in mice treated with vehicle (n ¼ 8 control) or sphingosine-1 phosphate (n ¼ 8 sphingosine-1 phosphate),
0.4 mg/kg/day intraperitoneally for 4 weeks (P ¼ 0.03). (B) Arterial blood pressure of mice treated with vehicle or sphingosine-1 phosphate as
under (A). Values are the means of eight animals per group. (C) Haematoxylin–eosin and atrial natriuretic peptide staining of heart sections of
mice treated with vehicle or sphingosine-1 phosphate as under (A). Photomicrographs show representative sections of myocardium (Scale
bar ¼ 20 mm).
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In the present work, we isolated and identified S1P in the plasma
of patients with Fabry disease at significantly higher concentrations
compared with those seen in control plasma. Females showed a
wider range of S1P concentrations than female controls, but the
difference was not significant. Interestingly, we found no significant
difference in plasma S1P levels between male and female Fabry
patients who shared a comparable penetrance of cardiovascular
remodelling, as previously shown.6 Moreover, there was a strong
correlation between S1P concentration and both CCA IMT and
LVM index, in males and females with Fabry disease. This indicates
that cardiovascular remodelling and plasma S1P levels are, at least
in part, independent of the level of residual circulating
a-galactosidase A, and that plasma S1P, unlike plasma Gb3 and
lyso-Gb3, may be considered as a marker of the severity of cardi-
ovascular remodelling in Fabry disease.14,15
Ceramide metabolism generates a cascade of bioactive lipids, all
of which carry a specific signalling capacity.16 This sphingolipid signal-
ling network is expressed in the cardiovascular system.17,18 In
healthy subjects, S1P is present in the plasma at higher levels than
in the tissues, and exists largely in forms bound to high-density lipo-
proteins.19 S1P is generated by the phosphorylation of sphingosine
by sphingosine kinases and is irreversibly degraded by a specific
lyase that is exclusively located at the endoplasmic reticulum.20
Sphingosine-1 phosphate has been shown to induce in vitro
VSMC proliferation, by a variety of signal transduction pathways
including ERK and RhoA,21,22 and hypertrophy of neonatal rat car-
diomyocytes.23 Our in vitro study showed that S1P promotes
marked proliferation of VSMCs in a dose-dependent manner.
These data demonstrate that S1P is a potent circulating growth-
promoting factor because its effect was observed at
concentrations similar to those measured in plasma from patients
with Fabry disease (plasma concentrations only 1.3 times greater
than in healthy controls). Interestingly, at lower S1P concen-
trations, the VSMC phenotype was mainly hypertrophic, whereas
at higher S1P concentrations the VSMC phenotype was predomi-
nantly hyperplasic. These findings suggest that both proliferative
mechanisms may be involved in the arterial remodelling of Fabry
disease, with the participation of the individual mechanisms
depending directly on plasma S1P levels. The mechanism respon-
sible for increased plasma S1P levels in patients with Fabry
disease has yet to be established.16
Overall results, i.e. the increase of plasma S1P concentrations and
the strong correlation between S1P concentrations and both CCA
IMT and LVM index in patients with Fabry disease, and the in vitro
effect of S1P on VSMCs, suggest that S1P may be a key factor that trig-
gers the development of LVH and arterial intima–media thickening in
Fabry disease. We therefore injected S1P into an in vivo model of
Fabry disease in mice. Animals developed cardiovascular remodelling
that was very similar to that observed in humans with Fabry disease.
Image analysis revealed a significant thickening of the aortic IMT rela-
tive to control animals. The predominant cellular component of the
arterial wall was VSMCs, as revealed by immunostaining fora-actinin.
Cardiac weight index was also significantly greater compared with
controls. Microscopic analysis revealed a marked hypertrophy of
cardiomyocytes at the origin of the increased cardiac mass as
assessed by diffuse ANP expression. Significant cardiovascular remo-
delling developed in S1P-treated mice after only 1 month of daily
injections (half-life of S1P, 3–5 min), demonstrating that S1P is also
a potent hypertrophic mediator in vivo.4 S1P-treated mice had
lower blood pressure than controls. This is consistent with previous
Figure 6 (A) Correlation between plasma sphingosine-1 phosphate levels and common carotid artery intima–media thickness (CCA IMT) in
the Fabry population. (B) Correlation between plasma sphingosine-1 phosphate levels and left-ventricular mass in the Fabry population.
(C) Correlation between plasma sphingosine-1 phosphate levels and CCA IMT in male and female patients with Fabry disease and controls.
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animal studies which reported that systemic administration of S1P
may reduce blood pressure.24
Sphingosine-1 phosphate interacts with high-affinity G-protein
coupled receptors that can sense very small changes in S1P level,
thus small increases in S1P may have functional and morphological
consequences.25 Receptors S1P1 –3 are widely expressed in endo-
thelial cells and VSMCs of the artery tree and in cardiomyo-
cytes,26–28 and their biological roles have been shown by the
generation of knockout mice. The importance of S1P1 in angiogen-
esis is exemplified by the embryonic lethality of S1P1 knockout.
29
There is evidence that S1P1 and S1P3 receptors promote,
whereas S1P2 receptors antagonize, VSMC proliferation in vitro in
response to S1P.30,31 Cardiomyocyte hypertrophy appears to be
mediated by S1P1 receptors as an anti-S1P1 receptor antibody
has been found to block S1P-mediated hypertrophy.23
Some reports have suggested that the biologically active high-
density lipoprotein compound S1P is responsible for anti-
atherogenic actions on vascular endothelial cells of the myocar-
dium.24,32 Recently, we showed that patients with Fabry disease
are somehow protected from atherosclerotic plaques relative to
controls with a similar number of cardiovascular risk factors.33
Our data suggest that the increased plasma S1P concentration in
patients with Fabry disease may be in part responsible for the car-
diovascular remodelling and the anti-atherogenic effect observed in
Fabry disease. These findings open new perspectives that have
implications for the treatment of cardiovascular complications in
Fabry disease.
In conclusion, our data provide evidence that S1P is a bioactive
mediator that participates in the development of cardiovascular
remodelling in patients with Fabry disease. Sphingosine-1
phosphate-treated mice developed cardiovascular anomalies
similar to those observed in patients with Fabry disease, further
supporting the potent cardiovascular effects of S1P. In addition,
the strong correlation of plasma S1P levels with LVH and with
increased CCA IMT, in the absence of arterial hypertension,
provide evidence of the role of S1P as a marker of the severity
of cardiovascular remodelling in Fabry disease.
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An indirect shot to the heart
Ali Khavandi1*, Toby Hall2, and Alan Bryan1
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A 49-year-old man presented with breathlessness. Chest X-ray (Panels A–C) showed a foreign body in line with the thoracic vertebra.
Further CT imaging confirmed a metallic object embedded in the right ventricle (Panels D–K). He had no history of cardiac or thoracic
surgery and no history of penetrating trauma. On further questioning it was discovered that he was shot in the back of the right knee
with an air-rifle pellet 27 years ago (Panel L). This had subsequently migrated into the venous system and embolized to the right heart.
Migration and venous or arterial embolization of penetrating foreign bodies are rare, but recognized.
If they result in obstruction, then percutaneous or surgical retrieval is indicated. In this patient, this finding was considered to be
incidental and unrelated to his symptoms. After joint cardiothoracic/interventional cardiology discussion, no further treatment was
recommended. He is due to have CT monitoring in 2 years.
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